OREX. Orexigen Therapeutics Receives Dispute Response Indicating FDA is Highly Supportive of Exploration of a Faster Path to Resubmission of the Contrave NDA
-- Light Study enrollment surpasses 7,000 patients; the Company plans to continue enrollment to approximately 9,000 patients by year end, speeding the time to interim analysis
http://finance.yahoo.com/news/orexigen-therapeutics-receives-dispute-response-110200473.html
-- Light Study enrollment surpasses 7,000 patients; the Company plans to continue enrollment to approximately 9,000 patients by year end, speeding the time to interim analysis
http://finance.yahoo.com/news/orexigen-therapeutics-receives-dispute-response-110200473.html
Index Prime
http://investorshub.advfn.com/Index-Prime-25623/
5-bagger contest on Dawgg.
http://investorshub.advfn.com/%22Dawgg%22-21519/
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
